- Home
- NAMM vs CSBR Comparison
NAMM vs CSBR Comparison
Compare NAMM & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAMM | CSBR |
|---|---|---|
| Founded | 2024 | 1985 |
| Country | Cayman Islands | United States |
| Employees | 1500 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.9M | 81.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NAMM | CSBR |
|---|---|---|
| Price | $1.85 | $6.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 5.6K |
| Earning Date | 04-02-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | $76.84 | $4.84 |
| Revenue Next Year | $85.06 | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $5.50 |
| 52 Week High | $11.63 | $9.63 |
Technical Indicators
Market Signals| Indicator | NAMM | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 54.56 |
| Support Level | $1.31 | $6.14 |
| Resistance Level | $2.38 | $6.96 |
| Average True Range (ATR) | 0.22 | 0.31 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 10.53 | 51.43 |
Price Performance
Historical ComparisonAbout NAMM Namib Minerals Ordinary Shares
Namib Minerals is a Pan-African multi-asset mining platform for precious and critical metals, particularly gold. The company is an established gold producer with an attractive portfolio of three gold mines in Zimbabwe, Africa. Its gold mines include How Mine, Mazowe Mine, and Redwing Mine. Its segments include the How Mine, the Mazowe Mine, and the Redwing Mine, and Others.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.